Brookline Capital Markets Predicts UNCY FY2030 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at Brookline Capital Markets raised their FY2030 EPS estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, June 30th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of $3.06 for the year, up from their prior forecast of $2.93. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

UNCY has been the subject of a number of other research reports. Wall Street Zen cut Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Noble Financial dropped their price target on shares of Unicycive Therapeutics from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday. Benchmark reduced their price objective on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research note on Wednesday. HC Wainwright decreased their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday. Finally, B. Riley Financial reiterated a “buy” rating and issued a $22.00 target price on shares of Unicycive Therapeutics in a research note on Tuesday. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.40.

Unicycive Therapeutics Stock Up 12.6%

Shares of UNCY opened at $5.28 on Thursday. The firm has a market cap of $144.62 million, a price-to-earnings ratio of -2.39 and a beta of 1.80. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $8.74. The company’s fifty day moving average is $7.46 and its 200-day moving average is $6.82.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UNCY. Vivo Capital LLC increased its position in Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after acquiring an additional 652,901 shares during the period. Millennium Management LLC bought a new position in shares of Unicycive Therapeutics during the 4th quarter worth about $5,856,000. Vanguard Group Inc. increased its holdings in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after purchasing an additional 52,925 shares during the period. Cantor Fitzgerald L. P. acquired a new position in shares of Unicycive Therapeutics during the fourth quarter valued at about $1,154,000. Finally, Geode Capital Management LLC lifted its stake in shares of Unicycive Therapeutics by 36.2% in the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after buying an additional 45,563 shares during the period. Institutional investors and hedge funds own 40.42% of the company’s stock.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial and Brookline Capital Markets reiterated a constructive long-term view, with Noble assigning an Outperform rating and $50 target while modeling strong 2027 earnings and Brookline raising its FY2030 EPS estimate. Analyst target update
• Positive Sentiment: Despite the FDA setback, the company said the agency did not raise concerns about OLC’s clinical efficacy or safety data and requested no additional clinical data, which leaves the door open for a future resubmission. FDA CRL summary
• Neutral Sentiment: Unicycive said it is in ongoing discussions with the FDA over labeling and packaging and remains optimistic about resolving the manufacturing issues, but there is still no clear timeline for approval. Investigation notice
• Negative Sentiment: Multiple law firms launched securities-fraud investigations into Unicycive after the FDA rejection, adding legal and reputational overhang for shareholders. Investor alert
• Negative Sentiment: Benchmark, Noble Financial, and HC Wainwright all lowered price targets, reflecting reduced near-term confidence after the regulatory setback. Price target cuts

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.